Good news! More to come!
"“Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google executive…
The four-year-old Isomorphic Labs was spun off from DeepMind in 2021 as a stand-alone subsidiary under Alphabet. In July, it announced deals to work on research with Eli Lilly & Co. and Novartis to leverage its AI technology — namely AlphaFold, its model that predicts a protein’s 3D structure — to discover therapeutics against multiple targets. ..."
Sir Demis Hassabis, PhD
Demis is our founder and CEO. He is also the founder and CEO of DeepMind.
No comments:
Post a Comment